CRL Related Major News
-
Charles River Laboratories (CRL) Misses Q1 EPS by 2c; Reaffirms Outlook
-
Charles River Laboratories (CRL) Tops Q4 EPS by 4c
-
Charles River Labs (CRL) Guides FY13 EPS Below Views
-
Charles River Laboratories (CRL) Tops Q2 EPS by 9c; Guides Higher
-
Charles River Laboratories (CRL) Tops Q1 EPS by 5c
-
Charles River Labs (CRL) Issues Solid Q4 Results; Reaffirms FY12 Outlook
-
Charles River Laboratories (CRL) Misses Q3 EPS by 1c; Tightens FY11 EPS Outlook
-
Charles River Labs (CRL) Tops Q2 EPS by 10c; Boosts FY11 Guidance
-
Charles River Laboratories Int's (CRL) Tops Q1 EPS by 6c
-
Charles River Labs (CRL) Tops Q4 EPS by 10c; Reaffirms Outlook
-
Investors In Charles River (CRL) Push For a Sale
-
Charles River (CRL) Posts Q3 non-GAAP EPS of $0.45, Shy of Views; Increases FY10 Outlook
-
Charles River Labs (CRL) Posts Q2 non-GAAP EPS of $0.49, Misses by 1c
-
Charles River (CRL) Makes Big Bet On China With $1.6B Deal for WuXi PharmaTech (WX), Shares Fall
-
Charles River Labs (CRL) Posts Q1 EPS of $0.45, Misses Views by 2c
-
Charles River Labs (CRL) posts Q4 EPS of $0.49, Beats by 5c; Guides FY10 EPS Below Street
-
Charles River Labs (CRL) to Suspend Operations at Preclinical Services Facility in MA; Sees FY09 EPS Above Prior Guidance
-
Charles River (CRL) Beats Q3 Views by 5c; Lowers FY09 EPS Guidance
-
Charles River Laboratories (CRL) Tops Q2 EPS by 8c; Narrow FY EPS Guidance Range
-
Charles River (CRL) Tops Q1 EPS by 5c; Guides In-line for FY09
-
Charles River Labs (CRL) Reports Q4 Adj-EPS of $0.59, Beats by 4c; Guides FY09
-
Charles River Labs (CRL) Reports Mixed Q3 Earnings; Cuts FY08 Outlook
-
Charles River Laboratories (CRL) Tops View By 6c; Issues Guidance; Boosts Buyback By $200 Million
-
Charles River Laboratories (CRL) Tops Q1 View; Reaffirms Outlook
-
Charles River Laboratories (CRL) Reports Q4 EPS of $0.65, Tops Street By 2c; Affirms FY08 Guidance
Back to CRL Stock Lookup
